PSNL (Personalis) Insider Ownership : 2.12 % (As of Dec. 11, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Personalis Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Personalis's insider ownership is 2.12%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Personalis's Institutional Ownership is 46.19%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Personalis's Float Percentage Of Total Shares Outstanding is 65.39%.

Personalis Insider Ownership Historical Data

The historical data trend for Personalis's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis Insider Ownership Chart

Personalis Historical Data

The historical data trend for Personalis can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Insider Ownership	2.74	2.76	2.72	2.68	2.65	2.94	2.31	2.31	2.31	2.12

Personalis Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Personalis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (NAS:PSNL) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

04X:Germany

Address

6600 Dumbarton Circle, Fremont, CA, USA, 94555

Website

https://www.personalis.com

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Executives

Richard Chen	officer: Chief Scientific Officer	C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Stephen Michael Moore	officer: General Counsel	C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Aaron Tachibana	officer: Chief Financial Officer	400 NORTH MCCARTHY BLVD, MILPITAS CA 95035
Christopher M Hall	officer: President	6600 DUMBARTON CIRCLE, FREMONT CA 94555
Myers Woodrow A Jr	director	1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Kenneth J Widder	director	10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Lonnie Shoff	director	C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
John Stephen West	director, officer: President and CEO	C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Lightspeed Venture Partners Select Iv, L.p.	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Olivia Kyusuk Bloom	director	C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Ken Ludlum	director
Arif Janmohamed	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed Ultimate General Partner Select Iv, L.l.c.	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed General Partner Select Iv, L.p.	other: Affiliate of 10% Owner	2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025